IA
PRLD icon

IFP Advisors’s Prelude Therapeutics PRLD Stock Holding History

IFP Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$3 – 5127
2025
Q4 		$3 Sell
1
-17
-94% -$29 ﹤0.01% 4867
2025
Q3 		$26 Sell
18
-16
-47% -$16 ﹤0.01% 4736
2025
Q2 		$28 Buy
+34
New +$29 ﹤0.01% 4835
2021
Q2 		– Sell
-1,194
Closed -$42.5K – 3190
2021
Q1 		$52K Buy
+1,194
New +$79.2K ﹤0.01% 1457

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

IFP Advisors's PRLD Position: Q1 2026 in Review

IFP Advisors sold out of Prelude Therapeutics (PRLD) in Q1 2026, closing a stake of 1 share — an estimated $3 sold.

IFP Advisors first reported a position in PRLD in Q1 2021 and held it in 4 quarters. The position peaked at $52K in Q1 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • IFP Advisors reported no remaining Prelude Therapeutics position as of Q1 2026 after selling out during the quarter.
  • IFP Advisors sold 1 Prelude Therapeutics share in Q1 2026, an estimated $3.
  • IFP Advisors first reported a position in Prelude Therapeutics in Q1 2021 and held it in 4 quarters.
  • IFP Advisors's Prelude Therapeutics position peaked at $52K in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.